K
Kwangmeyung Kim
Researcher at Korea Institute of Science and Technology
Publications - 386
Citations - 26932
Kwangmeyung Kim is an academic researcher from Korea Institute of Science and Technology. The author has contributed to research in topics: Drug delivery & Drug carrier. The author has an hindex of 82, co-authored 386 publications receiving 23214 citations. Previous affiliations of Kwangmeyung Kim include Korea University & Inha University.
Papers
More filters
Journal ArticleDOI
Multifunctional nanoparticles for multimodal imaging and theragnosis
TL;DR: This tutorial review will highlight the recent advances in the development of multifunctional nanoparticles and their biomedical applications to multimodal imaging and theragnosis as nanomedicine.
Journal ArticleDOI
Targeted delivery of low molecular drugs using chitosan and its derivatives.
TL;DR: The main objective of this review is to provide an insight into various target-specific carriers, based on chitosan and its derivatives, towards low molecular weight drug delivery.
Journal ArticleDOI
Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles
Hae Yun Nam,Seok Min Kwon,Seok Min Kwon,Hyunjin Chung,Hyunjin Chung,Seung Young Lee,Seung Hae Kwon,Hyesung Jeon,Y. H. Kim,Jae Hyung Park,Joon Kim,Songwook Her,Yu-Kyoung Oh,Ick Chan Kwon,Kwangmeyung Kim,Seo Young Jeong +15 more
TL;DR: Given such favorable properties including low toxicity, biocompatibility, and fast uptake by several nondestructive endocytic pathways, the HGC nanoparticles may serve as a versatile carrier for the intracellular delivery of therapeutic agents.
Journal ArticleDOI
Self-assembled hyaluronic acid nanoparticles for active tumor targeting.
Ki Young Choi,Hyunjin Chung,Hyunjin Chung,Kyung Hyun Min,Kyung Hyun Min,Hong Yeol Yoon,Kwangmeyung Kim,Jae Hyung Park,Ick Chan Kwon,Seo Young Jeong +9 more
TL;DR: Interestingly, the concentration of HA-NPs in the tumor site was dramatically reduced when mice were pretreated with an excess of free-HA, implying that HA-nPs can accumulate into the tumor sites by a combination of passive and active targeting mechanisms.
Journal ArticleDOI
Polymeric nanomedicine for cancer therapy
TL;DR: The characteristics of cancer that provide nanodrug targeting opportunities are highlighted and rational approaches for future development of polymeric nanomedicines are discussed.